Compare Applovin Corporation (APP) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Applovin Corporation vs Humana Inc — how do they compare? Applovin Corporation trades at $506 (market cap $170.31B), while Humana Inc trades at $396.45 (market cap $47.09B). The key difference: Applovin Corporation is far larger — about 3.6× Humana Inc's market cap, and Humana Inc pays a 0.9% dividend while Applovin Corporation pays none. Which is the better fit depends on your goals.
| APP | HUM | |
|---|---|---|
Market Cap | $170.31B | $47.09B |
Sector | Technology | Health |
52-Week High | $733.60 | $409.42 |
52-Week Low | $335.10 | $163.67 |
Enterprise Value | $171.07B | $56.13B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AppLovin trades at $506.98, down 2.58% today, with a bullish technical setup near pivot point support at $504. The company shows exceptional fundamentals with 59% revenue growth in Q1 2026 and net margins exceeding 64%. Analyst consensus remains strongly bullish with an $644.09 price target, supported by expanding e-commerce advertising share and AI-driven platform growth noted in recent Jefferies research.
The outlook remains positive given consistent earnings beats and projected revenue growth to $6.2B in 2026. Primary risks include premium valuation multiples (P/E 44.09) and competitive pressure in mobile advertising. The stock offers growth exposure but requires monitoring of execution against high expectations.
Humana (HUM) trades at $392.22, down 1.39% on the day, with technical indicators showing a bullish trend despite near-term overbought signals. The company reported revenue growth to $129.66 billion in 2025 but faces margin compression, with net income margin declining to 0.82%. Recent news highlights strategic shifts, including the $900 million divestiture of its Gentiva stake and expansion of Medicaid contracts, while legal investigations into fiduciary duties and healthcare cost disclosures present headwinds.
The stock's outlook is mixed: bullish technicals and revenue growth contrast with margin pressures and legal risks. Analysts are cautious, with a consensus price target of $327.07 below the current price, suggesting limited upside. Investment opportunities lie in Humana's strategic focus on profitability and CenterWell growth, but risks include regulatory scrutiny and execution challenges in a competitive healthcare landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applovin Corporation
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
